Alpha-2 adrenergic agonists, including medetomidine, have been increasingly identified as adulterants in the United States opioid supply. Withdrawal or complicated presentations related to these agents can produce severe symptoms such as agitation and nausea that may not respond to standard care. High-dose dexmedetomidine infusion has been used to manage this toxidrome in emergency and critical care settings, and affected patients are frequently transferred from community emergency departments to tertiary critical care units while receiving continuous infusion therapy. This study aimed to describe interventions and outcomes for patients undergoing interfacility transport while receiving dexmedetomidine for suspected medetomidine withdrawal to help inform safe prehospital and transport practices.
The authors performed a retrospective observational cohort study of consecutive non-intubated patients who were receiving a dexmedetomidine infusion for suspected medetomidine withdrawal and were transported by a regional critical care transport agency. The study period covered March 2024 through February 2026. The investigation identified presenting clinical characteristics, characterized withdrawal symptoms, and recorded the incidence and indications for supplemental medical therapy provided during transport. The team also identified the prevalence of hemodynamic instability, hypoxia, and the need for advanced airway interventions during transport.
The cohort comprised 100 patients transported while on a dexmedetomidine infusion for management of suspected medetomidine withdrawal. On arrival to or prior to crew arrival, common clinical features included agitation in 53% and nausea/vomiting in 58% of patients. Cardiac rhythm and blood pressure abnormalities were frequent before or upon crew arrival: tachycardia or bradycardia was documented in 62% and hypertension in 71% of patients. The abstract does not report patient age distribution, comorbidities, or specific dexmedetomidine dosing regimens.
During interfacility transport, additional therapies were relatively uncommon. Specific in-transport interventions included:
No patients received alternative sedative infusions in place of dexmedetomidine while in transport. The study did not report details about which sedatives or antiemetics were used or the dosages administered.
Hemodynamic and respiratory observations during transport demonstrated that many patients remained hypertensive: 78% had systolic blood pressure (SBP) >140 mmHg. A substantial subset experienced more severe hypertension, with 39% meeting criteria for profound hypertension (SBP >180 mmHg or diastolic blood pressure >110 mmHg). Cardiac rate abnormalities observed during transport included tachycardia (heart rate >120) in 35% and bradycardia (heart rate <50) in 6%.
Hypotension (SBP <90 mmHg) occurred in 6% of patients. Hypoxia was uncommon: 3% experienced an oxygen saturation (SpO2) <90% and 3% were treated with supplemental oxygen. Crucially, no patients required advanced airway management while in transport. The requirement for vasopressor support was very rare (1% received a vasoactive infusion). The abstract does not provide time-to-event data, duration of transport, or progressive physiology over the course of transfer.
In this cohort of 100 non-intubated patients transported on dexmedetomidine for suspected medetomidine withdrawal, patients were commonly hypertensive and only rarely hypoxic or in need of advanced airway interventions. While a minority required additional antiemetic or sedative medications, the majority remained clinically stable on the dexmedetomidine infusion alone. Need for vasopressors during transport was rare.
These findings support the feasibility and relative safety of continuing alpha-2 agonist therapy with dexmedetomidine during interfacility transport for this toxidrome, when patients are non-intubated. The authors emphasize early recognition of the syndrome and institution of pharmacologic alpha-2 agonism as likely important components of prehospital management for patients exposed to medetomidine-adulterated substances.
The abstract does not report several details that would inform broader interpretation and operational planning: specific dexmedetomidine dosing strategies, duration of infusion prior to transport, patient comorbidities, exact antiemetic and sedative agents used, transport distances or durations, and longer-term clinical outcomes after arrival. These data were not reported in the source abstract and therefore are not summarized here.